SCHEMBL3706089

SCHEMBL3706089

CC(=O)C1=C(O)C(=O)N(CCc2cccc(C(F)(F)F)c2)C1c1ccc(Br)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP7 Q93009 1/20 0.66
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
TP53 P04637 1/20 0.52
MDM2 Q00987 1/20 0.52
RXFP1 Q9HBX9 4/20 0.50
HTT P42858 2/20 0.48
FPR1 P21462 1/20 0.48
HIF1A Q16665 1/20 0.48
KDM4E B2RXH2 2/20 0.47
ATM Q13315 1/20 0.47
HPGD P15428 3/20 0.47
ALDH1A1 P00352 3/20 0.47
ALOX15 P16050 2/20 0.46
POLB P06746 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
LMNA P02545 1/20 0.45
CCR1 P32246 1/20 0.44
CCR2 P41597 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3714413 0.87 USP7 (0.73) USP7MEN1KMT2ATP53MDM2
SCHEMBL3709177 0.86 USP7 (0.57) USP7MEN1KMT2ATP53MDM2
SCHEMBL3709475 0.83 KDM4E (0.59) USP7MEN1KMT2ATP53MDM2
SCHEMBL3712732 0.83 USP7 (0.67) USP7MEN1KMT2ATP53MDM2
SCHEMBL3707749 0.80 USP7 (0.71) USP7MEN1KMT2ATP53MDM2
SCHEMBL3709928 0.79 USP7 (1.00) USP7MEN1KMT2ATP53MDM2
SCHEMBL3704381 0.79 MEN1 (0.70) USP7MEN1KMT2ATP53MDM2
SCHEMBL6776151 0.79 MEN1 (0.73) USP7MEN1KMT2ATP53MDM2
SCHEMBL3714403 0.78 USP7 (0.69) USP7MEN1KMT2ATP53MDM2
SCHEMBL3709046 0.78 USP7 (0.78) USP7MEN1KMT2ATP53MDM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO claimed
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP claimed
US-20220125760-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) UNIVERSITÉ PAUL SABATIER TOULOUSE III (FR) 2022-04-28 US disclosed
EP-3923987-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2021-12-22 EP disclosed
WO-2020165315-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2020-08-20 WO disclosed
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO disclosed
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO disclosed
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP disclosed
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP disclosed